title: Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
authors.forename: Vlachaki
authors.initials: V
authors.lastname: Efthimia
authors.forename: Nikolaos
authors.initials: N
authors.lastname: Neokleous
authors.forename: Alexandra
authors.initials: A
authors.lastname: Agapidou
authors.forename: Marina
authors.initials: M
authors.lastname: Economou
authors.forename: Evaggelia
authors.initials: E
authors.lastname: Vetsiou
authors.forename: Aikaterini
authors.initials: A
authors.lastname: Teli
authors.forename: Vasileios
authors.initials: V
authors.lastname: Perifanis
mesh_terms: D000328:Adult; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D015913:Chelation Therapy / Q000009:adverse effects*; D002648:Child; D002675:Child, Preschool; D000077588:Deferasirox; D000077543:Deferiprone; D005260:Female; D006115:Greece / Q000453:epidemiology; D006801:Humans; D053565:Hypercalciuria / Q000209:etiology; D033461:Hyperuricemia / Q000209:etiology; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D053040:Nephrolithiasis / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology / Q000209:etiology; D011183:Postoperative Complications / Q000097:blood / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D011728:Pyridones / Q000627:therapeutic use; D013156:Splenectomy; D065227:Transfusion Reaction; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult; D017086:beta-Thalassemia / Q000097:blood / Q000150:complications* / Q000601:surgery / Q000628:therapy
chemical_list: D001565:Benzoates; D007502:Iron Chelating Agents; D011728:Pyridones; D014230:Triazoles; D000077543:Deferiprone; D000077588:Deferasirox